Transcriptional regulator The basic helix-loop-helix leucinezipper (bHLHZipper) protein family includes c-Myc. The c-MYC protein's target genes are involved in a variety of cellular processes, including the cell cycle, survival, protein synthesis, cell adhesion, and the expression of microRNAs. In addition, c-Myc, one of the four factors required for the induction of pluripotent stem (iPS) cells from somatic cells, is thought to contribute to the maintenance of cancer stem-like cells (CSCs). The majority of c-Myc'sbiologicalactivities necessitate heterodimerization with its activation partner Max.
Additionally, c-Myc is a component of a dynamic network, which interacts selectively with different transcriptional coregulators, histone-modifying enzymes, and members of the network. Tumorigenesis is linked to c-MYC expression that is dysregulated as a result of gene amplification, retroviral insertion, or chromosomal translocation. One extremely promising target for cancer treatment is c-Myc.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V2724 | 10074-G5 | 413611-93-5 | 10074-G5 is a potent inhibitor of c-Myc-Max dimerization and interaction with an IC50 of 146 μM and with anticancer activities. |
|
V108677 | 4-O-Methyl-ascochlorin | 38561-40-9 | 4-O-methyl-ascoclorin (compound MAC) is a derivative of ascoclorin. |
|
V1587 | 10058-F4 | 403811-55-2 | 10058-F4 (10058F4; 10058 F4) is a novel potent and selective c-Myc inhibitor with potential antineoplastic activity. |
|
V104825 | Cotylenin A | 12708-37-1 | Cotylenin A is a phenanthroquinone compound that synergizes with vitamin K2 to induce monocyte differentiation and growth arrest, while inhibiting c-Myc expression and inducing cyclin G2 expression in human leukemia HL-60 cells. |
|
V112541 | DL78 | 132993-79-4 | DL78 is a potent antimitotic agent. |
|
V114618 | GQC-05 | 501662-77-7 | GQC-05 (NSC338258) is an elliptic pyridine derivative and a highly efficient and selective stabilizer for c-Myc G-tetrachain (c-Myc G4), with a KD value between 0.1 and 1.43 μM. |
|
V113262 | Hydroxyrubicin | 73113-90-3 | Hydroxyrubicin is an anti-tumor drug. |
|
V120315 | Inosine-5'-diphosphate disodium | 54735-61-4 | Inosine-5'-bisphosphate disodium (IDP disodium) is a bait substrate for NM23-H2. |
|
V51576 | IRES-C11 | 342416-30-2 | IRES-C11 is a selective translation inhibitor that binds to the c-MYC internal ribosome entry site. |
|
V115543 | KI-MS2-008 | KI-MS2-008 is a selective Max binder. | |
|
V4012 | ML327 | 1883510-31-3 | ML327 is a novel potent MYC blocker which also de-represses E-cadherin transcription, partially reverses EMT (Epithelial-to-Mesenchymal Transition), and inhibits cancer cell invasiveness and tumor cell migration in vitro and in vivo. |
|
V118270 | MYC-IN-4 | 3109265-41-7 | MYC-IN-4 is a MYC inhibitor. |
|
V37599 | MYCi361 (NUCC-0196361) | 2289690-31-7 | MYCi361 (NUCC0196361) is a novel and potent MYC inhibitor (Kd = 3.2 μM) with potential anticancer activity, it demonstrated a narrow therapeutic index. |
|
V37600 | MYCi975 (NUCC-0200975) | 2289691-01-4 | MYCi975 (NUCC-0200975), anMYCi361analog, is a novel, orally bioactive and potent MYC inhibitor (Kd = 3.2 μM) with potential anticancer activity. |
|
V22075 | Mycro3 | 944547-46-0 | Mycro 3 is an orally bioactive, potent and specific inhibitor of Myc-Max dimerization. |
|
V111978 | NUCC-0201642 | 2289691-70-7 | NUCC-0201642 is a c-MYC inhibitor with an IC50 > 40 μM. |
|
V116638 | Y502-2304 | 741278-95-5 | Y502-2304 is a c-Myc G-tetrachain stabilizer. |
|
V109999 | ZD-1-186 | ZD-1-186 is a non-degradable molecular gel that can effectively inhibit the expression of MYC in diffuse large B-cell lymphoma cells and significantly induce the expression of CDKN1A (p21). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
